Uploaded December 2024 | Updated September 2026, 3 weeks ago
Welcome to another insightful episode of #ExpertTalk by EverythingALS!
In this session, we bring you the latest updates on CNM-Au8, a groundbreaking therapeutic candidate from Clene Nanomedicine. Our expert speakers, Rob Etherington (Chief Executive Officer, Clene Nanomedicine) and Dr. Marjan Sepassi (Vice President, Medical Affairs, Clene Nanomedicine), delve into the long-term evidence supporting CNM-Au8 and the Expanded Access Program (EAP) update.
Discover how Clene Nanomedicine’s innovative approach to neurodegenerative diseases is paving new pathways for ALS treatment. Rob Etherington shares strategic insights, while Dr. Marjan Sepassi provides a medical perspective on CNM-Au8’s clinical impact and the value of the EAP for patients and caregivers.
What You’ll Learn in This Episode:
- Key findings from long-term evidence on CNM-Au8’s efficacy
- Insights on the Expanded Access Program (EAP) for ALS patients
- Strategic and medical perspectives from Clene Nanomedicine’s leadership team
Don’t miss this chance to stay informed about the future of ALS treatment. Watch now and be part of the conversation.
Timestamps:
► 0:00 Introduction
► 2:15 Meet the Experts: Rob Etherington & Dr. Marjan Sepassi
► 5:30 What is CNM-Au8?
► 12:45 Long-term Evidence and Clinical Insights
► 25:10 Expanded Access Program (EAP) Update
► 40:00 Q&A with Viewers
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #EverythingALS #ALSResearch #CleneNanomedicine #CNMAu8 #ALSUpdate #ALSCommunity #NeurodegenerativeDisease #ALSClinicalTrials #RobEtherington #MarjanSepassi #ExpandedAccessProgram #ALSBreakthroughs #MedicalResearch #HealthcareInnovation
If you’re interested in the latest developments in ALS research and treatment, hit the like button, subscribe, and turn on notifications for future updates. Share this video with others who may benefit from this essential information.
Welcome to another insightful episode of #ExpertTalk by EverythingALS!
In this session, we bring you the latest updates on CNM-Au8, a groundbreaking therapeutic candidate from Clene Nanomedicine. Our expert speakers, Rob Etherington (Chief Executive Officer, Clene Nanomedicine) and Dr. Marjan Sepassi (Vice President, Medical Affairs, Clene Nanomedicine), delve into the long-term evidence supporting CNM-Au8 and the Expanded Access Program (EAP) update.
Discover how Clene Nanomedicine’s innovative approach to neurodegenerative diseases is paving new pathways for ALS treatment. Rob Etherington shares strategic insights, while Dr. Marjan Sepassi provides a medical perspective on CNM-Au8’s clinical impact and the value of the EAP for patients and caregivers.
What You’ll Learn in This Episode:
- Key findings from long-term evidence on CNM-Au8’s efficacy
- Insights on the Expanded Access Program (EAP) for ALS patients
- Strategic and medical perspectives from Clene Nanomedicine’s leadership team
Don’t miss this chance to stay informed about the future of ALS treatment. Watch now and be part of the conversation.
Timestamps:
► 0:00 Introduction
► 2:15 Meet the Experts: Rob Etherington & Dr. Marjan Sepassi
► 5:30 What is CNM-Au8?
► 12:45 Long-term Evidence and Clinical Insights
► 25:10 Expanded Access Program (EAP) Update
► 40:00 Q&A with Viewers
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #EverythingALS #ALSResearch #CleneNanomedicine #CNMAu8 #ALSUpdate #ALSCommunity #NeurodegenerativeDisease #ALSClinicalTrials #RobEtherington #MarjanSepassi #ExpandedAccessProgram #ALSBreakthroughs #MedicalResearch #HealthcareInnovation
If you’re interested in the latest developments in ALS research and treatment, hit the like button, subscribe, and turn on notifications for future updates. Share this video with others who may benefit from this essential information.
